Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center
United European Gastroenterology Journal · 2023
DOI: 10.1002/ueg2.12376 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2023. Verfasst von Mathias Jachs und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Hepatitis B Surface Antigens, Hepatitis B, Chronic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims Treatment indications for chronic hepatitis B (CHB) differ among recommendations by European Association for the Study of the Liver (EASL), American Association for the Study of Liver Diseases (AASLD) and World Health Organization (WHO). We aimed to assess treatment eligibility and linkage to therapy at a large tertiary care center.
Methods
All CHB patients who were evaluated for treatment at the Vienna General Hospital between January 2010 and December 2020 were retrospectively included. Clinical, virological, and long‐term treatment efficacy data were analyzed.
Results
A total of 751 CHB patients were included (53.3% male; median age: 39.5 years; HBeAg‐positive: 10.8%). The median Hepatitis B Virus (HBV)‐DNA and HBsAg levels were 569 (68–11,750) IU/mL and 3467.65 (620.05–11,935.43) IU/mL, respectively. Overall, 9.2% of patients had severe fibrosis/cirrhosis, and 5.7% were coinfected with hepatitis D virus (HDV), which was highly prevalent in cirrhosis. According to the recent EASL nomenclature, 3.2% of patients had HBeAg‐positive chronic infection, 7.6% had HBeAg‐positive chronic hepatitis, 58.9% had HBeAg‐negative chronic infection, and 30.4% had HBeAg‐negative chronic hepatitis. At the time of evaluation, 36.4% had HBV‐DNA >2000 IU/mL, and 37.3% showed alanine aminotransferase >40 U/L. Ultimately, 26.9% (EASL), 29.0% (AASLD) and 23.4% (WHO) met the treatment criteria. Treatment was initiated in most patients, mainly with tenofovir (61.8%) or entecavir (34.9%). Treatment efficiently suppressed HBV‐DNA in all patients; however, HBsAg loss was observed only in 2.8% at 5 years of therapy.
Conclusions
Severe fibrosis/cirrhosis was found in 9.2% of CHB patients at presentation, and 23.4%–29.5% met current treatment recommendations with a high treatment uptake of 79.8%–89.2% among eligible patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
- Division of Clinical Virology, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Mathias Jachs, Lorenz Balcar, Mattias Mandorfer, Thomas Reiberger
Zitieren
APA
Jachs, M., Sauberer, R., Stiegler, A., Dechêne, A., Tazreiter, R., Hartl, L., Bauer, D., Balcar, L., Strassl, R., Mandorfer, M., Trauner, M., Munda, P., Ferenci, P., & Reiberger, T. (2023). Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12376
Vancouver
Jachs M, Sauberer R, Stiegler A, Dechêne A, Tazreiter R, Hartl L, et al. Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center. United European Gastroenterology Journal. 2023. doi:10.1002/ueg2.12376
BibTeX
@article{Jachs2023,
author = {Jachs, Mathias and Sauberer, Raphael and Stiegler, Alexander and Dechêne, Anton and Tazreiter, Raphael and Hartl, Lukas and Bauer, David and Balcar, Lorenz and Strassl, Robert and Mandorfer, Mattias and Trauner, Michael and Munda, Petra and Ferenci, Peter and Reiberger, Thomas},
title = {Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center},
journal = {United European Gastroenterology Journal},
year = {2023},
doi = {10.1002/ueg2.12376}
}
EUVIMED